Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer

Chemotherapy

Volumn 55, Issue 3, 2009, Pages 155-160

  Somali, Isil ^a   Alacacioglu, Ahmet ^b   Tarhan, Mustafa Oktay ^a   Meydan, Nezih ^c   Erten, Cigdem ^a   Usalp, Songul ^a   Yilmaz, Ugur ^d  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Izmir Research and Training Hospital   (Turkey)

^c ADNAN MENDERES UNIVERSITY   (Turkey)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Combination chemotherapy; Gemcitabine; Metastatic breast cancer

Indexed keywords

AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; BILIRUBIN; CISPLATIN; CREATININE; FUROSEMIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE; TAXOIDS;

EID: 65449152268     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214143     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Ca ncer J Clin 2008;58: 71-96.
2. Decatris MP, Sundar S, O'Byrne KJ: Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004;4:53-81.
3. Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, Veeder MH, Cannon MW, Ingle JN: Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol 2005;28:195-200.
4. Ichinose I, Hamada Y, Mitsuyama S, Ishikawa E, Ikeda T, Kobayashi S, Horikoshi N, Tamura K: Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer. Chemotherapy 2008;54:379-385.
5. Massacesi C, La Cesa A, Marcucci F, Pilone A, Rocchi MB, Zepponi L, Santini D, Tonini G, Burattini L: Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology 2006;70: 294-300.
6. Lee SH, Lee J, Park J, Park SH, Lee KE, Lee SI, Nam E, Park JO, Kim K, Jung CW, Park YS, Yoon SS, Kang WK, Lee MH, Park K, Im YH: Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 2004;21:223-231.
7. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I: Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004;43: 18 6 -18 9.
8. Oksuzoglu B, Abali H, Hayran M, Yildirim N, Bud a koglu B, Z engin N: Capec itabine and cisplatin combination is an active and welltolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes. Chemotherapy 2008;54:352-356.
9. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A: Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002;62:2-8.
10. Brodowicz T, Kostler WJ, Moslinger R, Tomek S , Vaclavik I, Herscovici V, Wiltschke C, Steger GG, Wein W, Seifert M, Kubista E, Zielinski CC: Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 2000;9: 338-342.
11. Burch PA, Maillard J, Hillman D: Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer (MBC) and failure on prior chemotherapy: a North Central Cancer Treatment Group study (abstract). Breast Cancer Res Treat 20 00;64: 81.
12. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-2736.
13. Chaudhry S, Abdel-Rahman H, Patil R, Mansour R, Mills G, Burton GV: Prospective phase II study of weekly cisplatin gemcitabine in refractory metastatic breast cancer (abstract 430). Proc Am Soc Clin Oncol 2000;19: 111a .
14. de la Pena HF, Tellez E , Bastarrachea J: Gemcitabine plus cisplatin as a palliative treatment in metastatic or refractory breast cancer (abstract). Proc Am Soc Clin Oncol 2001;20:60b.
15. Doroshow JH, Tetef M, Margolin K: Significant activity of gemcitabine and cisplatin in both heavily and minimally pretreated metastatic breast cancer patients: a California Cancer Consortium/Loyola University Chicago trial (abstract). Proc Am Soc Clin Oncol 2000;19:155a.
16. Bull T, Anderson M, Lippman J, et al: A phase II trial of cis-dichloro platinum II in breast and ovarian carcinomas (abstract). Proc Am Soc Clin Oncol 1978;19:87.
17. Forastiere AA, Hakes TB, Witttes JT, et al: Cisplatin in the treatment of metastatic breast carcinoma: a prospective randomized trial of two dosage schedules. Am J Clin Oncol 1982;5: 243-247.
18. Martino S, Samal BA, Singhakowinta A, et al: A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules. J Cancer Res Clin Oncol 1984;108:354-356.
19. Ostrow S, Egorin M, Aisner J, et al: High-dose cis-diaminedichloro- platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials 1980;3:23-27.
20. Yap H, Salem P, Hortobagyi GN, et al: Phase II study of cis-dichlorodiamineplatinum (II) in advanced breast cancer. Cancer Treat Rep 1978;62:405-408.
21. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ: Interaction between cisplatin and gemcitabi-ne in vitro and in vivo. Semin Oncol 1995;22(suppl 11):72-79.
22. Galvez CA, Calmarini F, Curie M: Monthly cisplatin and gemcitabine as second line chemotherapy for patients with advanced breast cancer (abstract). Breast Cancer Res Treat 2000;64: 81.
23. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS: Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000;18:2245-2249.
24. Heinemann V, Stemmler HJ, Wohlrab A, Bosse D, Losem C, Kahlert S, Rautke G: High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline-and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2006;57: 640-646.
25. Seo JH, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, Kim AR, Lee JB, Koo BH: Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol 2007;59:269-274.
26. Fuentes H, Calderillo G, Alexander F, Ramirez M, Avila E, Perez L, Aguirre G, Oñate-Ocaña LF, Gallardo D, Otero J: Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. Anticancer Drugs 2006;17:565-570.
27. Ales-Martinez JE, Hernandez S, Sanchez-Escribanao R, Aramburo P: Tailored lowdose gemcitabine-cisplatine combination is a feasible and effective treatment in heavily pretreated advanced breast cancer patients. Proc Am Soc Clin Oncol 2005;24:A837.
28. Taş F, Güney N, Derin D, Camlica H, Aydiner A, Topuz E: Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with antrhacycline and taxane-pre-treated metastatic breast cancer. Invest New Drugs 20 08;26: 363 -368.
29. Sánchez-Escribano Morcuende R, Alés-Martinez JE, Aramburo González PM: Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracy- cline-containing regimens. Clin Transl Oncol 2007;9:459-464.
30. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Tharavichitkul E, Trakultivakorn H, Somwangprasert A, et al: Gemcitabine plus cisplatin: a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy. Gan To Kagaku Ryoho 2006;33:761-766.